4815-34-3

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2-amino-5-phenylthiophene-3-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its chemical structure allows for the creation of a wide range of pharmaceutical compounds, making it a valuable asset in drug development.
As a pharmaceutical intermediate, Ethyl 2-amino-5-phenylthiophene-3-carboxylate plays a crucial role in the development of new medications. Its unique chemical properties enable the synthesis of a variety of drug compounds, contributing to the advancement of pharmaceutical research and the creation of novel therapeutic options.

Upstream product

• 122-78-1 phenylacetaldehyde 
• 105-56-6 ethyl 2-cyanoacetate 
• 103-82-2 phenylacetic acid 
• 60-12-8 2-phenylethanol 
• 101-41-7 benzeneacetic acid methyl ester 
• 67-56-1 methanol 
• 14770-84-4 2-amino-5-phenylthiophene-3-carboxylic acid 
• 100-52-7 benzaldehyde 
• 10137-67-4 ethyl 3-cyanopropionate 
• 1431470-42-6 2-tert-butoxycarbonylamino-5-phenylthiophene-3-carboxylic acid ethyl ester 
• 1260664-49-0 ethyl 5-bromo-2-[[(tert-butoxy)carbonyl]amino]thiophene-3-carboxylate 
• 1262235-71-1 ethyl 2-amino-5-phenyl-4,5-dihydrothiophene-3-carboxylate 

Downstream Products

• 18593-61-8 2-benzyl-6-phenyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 18593-59-4 2-methyl-6-phenyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 151258-63-8 ethyl 2-(1-pyrrolyl)-5-phenylthiophen-3-carboxylate 
• 103357-77-3 2-ethyl-6-phenyl-8H-<1,3,4>thiadiazolo<3,2-a>thieno<2,3-d>pyrimidin-8-one 
• 134878-72-1 5-Chloro-10-phenyl-8H-thieno<2',3':4,5>pyrimido<2,1-a>phthalazin-8-one 
• 120131-29-5 methyl (4,5,6,7-tetrahydro-5-methoxycarbonyl-4-oxo-2-phenylthieno<2,3-b>pyridin-6-yl)acetate 
• 120131-27-3 dimethyl 3-(3-ethoxycarbonyl-5-phenyl-2-thienylamino)pent-2-enedioate 
• 41940-46-9 2-amino-5-phenylthiophene hydrochloride 
• 111849-29-7 2-Amino-5-phenylthiophene-3-carboxylic acid hydrazide 
• 122945-78-2 3-(4-Bromo-phenyl)-7-phenyl-thiazolo[3,2-a]thieno[2,3-d]pyrimidin-5-one 
• 103344-17-8 2-(methylthio)-6-phenyl-8H-[1,3,4]thiadiazolo[3,2-a]thieno[2,3-d]pyrimidin-8-one 
• 103344-19-0 2,6-Diphenyl-[1,3,4]thiadiazolo[3,2-a]thieno[2,3-d]pyrimidin-8-one 
• 124009-47-8 2-(3-Allyl-thioureido)-5-phenyl-thiophene-3-carboxylic acid ethyl ester 
• 72625-10-6 5-phenyl-2-(3-phenyl-thioureido)-thiophene-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Microwave-assisted synthesis of 2-aminothiophene derivatives via improved gewald reactions

In this paper, a new and efficient method was developed to prepare 2-aminothiophene derivatives through improved Gewald reaction. Thirty-one final products were synthesized under microwave radiation for 30 min with 57%-95% isolated yields. All the product

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex i

The successful treatment of Helicobacter pylori infections is becoming increasingly difficult due to the rise of resistance against current broad spectrum triple therapy regimens. In the search for narrow-spectrum agents against H. pylori, a high-throughp

Synthesis and evaluation of thiophene based small molecules as potent inhibitors of Mycobacterium tuberculosis

Herein, we report the synthesis and anti-tubercular studies of novel molecules based on thiophene scaffold. We identified two novel small molecules 4a and 4b, which demonstrated 2-fold higher in vitro activity (MIC99: 0.195 μM) compared to firs

ACLY INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.

Thiourea participation in [3+2] cycloaddition with donor-acceptor cyclopropanes: A domino process to 2-amino-dihydrothiophenes

The Yb(OTf)3-catalyzed [3+2] cycloaddition of donor-acceptor cyclopropanes with thiourea offers an efficient route to diverse 2-amino-4,5-dihydrothiophenes (up to 92% yield), in which optically active 2-amino-dihydrothiophenes can be produced f

Subtle modifications to a thieno[2,3-d]pyrimidine scaffold yield negative allosteric modulators and agonists of the dopamine D2 receptor

We recently described a structurally novel series of negative allosteric modulators (NAMs) of the dopamine D2 receptor (D2R) based on thieno[2,3-d]pyrimidine 1, showing it can be structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic carbocycles). We identify analogues with diverse pharmacology at the D2R including NAMs with sub-μM affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).

Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2,4-diones as inhibitors of HIV reverse transcriptase-associated RNase H

Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) is the only HIV enzymatic function not targeted by current antiviral drugs. Although various chemotypes have been reported to inhibit HIV RNase H, few have s

A Thieno[2,3- d]pyrimidine Scaffold Is a Novel Negative Allosteric Modulator of the Dopamine D2 Receptor

Recently, a novel negative allosteric modulator (NAM) of the D2-like dopamine receptors 1 was identified through virtual ligand screening. This ligand comprises a thieno[2,3-d]pyrimidine scaffold that does not feature in known dopaminergic ligands. Herein, we provide pharmacological validation of an allosteric mode of action for 1, revealing that it is a NAM of dopamine efficacy and identify the structural determinants of this allostery. We find that key structural moieties are important for functional affinity and negative cooperativity, while functionalization of the thienopyrimidine at the 5- and 6-positions results in analogues with divergent cooperativity profiles. Successive compound iterations have yielded analogues exhibiting a 10-fold improvement in functional affinity, as well as enhanced negative cooperativity with dopamine affinity and efficacy. Furthermore, our study reveals a fragment-like core that maintains low μM affinity and robust negative cooperativity with markedly improved ligand efficiency.

Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality

CB2-based therapeutics show strong potential in the treatment of diverse diseases such as inflammation, multiple sclerosis, pain, immune-related disorders, osteoporosis and cancer, without eliciting the typical neurobehavioral side effects of CB1 ligands. For this reason, research activities are currently directed towards the development of CB2 selective ligands. Herein, the synthesis of novel heterocyclic-based CB2 selective compounds is reported. A set of 2,5-dialkyl-1-phenyl-1H-pyrrole-3-carboxamides, 5-subtituted-2-(acylamino)/(2-sulphonylamino)-thiophene-3-carboxylates and 2-(acylamino)/(2-sulphonylamino)-tetrahydrobenzo[b]thiophene-3-carboxylates were synthesized. Biological results revealed compounds with remarkably high CB2 binding affinity and CB2/CB1 subtype selectivity. Compound 19a and 19b from the pyrrole series exhibited the highest CB2 receptor affinity (Ki= 7.59 and 6.15 nM, respectively), as well as the highest CB2/CB1 subtype selectivity (～70 and ～200-fold, respectively). In addition, compound 6b from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki= 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1). Compound 6b showed a full agonism, while compounds 19a and 19b acted as inverse agonists when tested in an adenylate cyclase assay. The present findings thus pave the way to the design and optimization of heterocyclic-based scaffolds with lipophilic carboxamide and/or retroamide substituent that can be exploited as potential CB2 receptor activity modulators.